Transgenic sickle mice have vascular inflammation
- 15 May 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (10) , 3953-3959
- https://doi.org/10.1182/blood-2002-10-3313
Abstract
Inflammation may play an essential role in vaso-occlusion in sickle cell disease. Sickle patients have high white counts and elevated levels of serum C-reactive protein (CRP), cytokines, and adhesion molecules. In addition, circulating endothelial cells, leukocytes, and platelets are activated. We examined 4 transgenic mouse models expressing human α- and sickle β-globin genes to determine if they mimic the inflammatory response seen in patients. These mouse models are designated NY-S, Berk-SAntilles, NY-S/SAntilles (NY-S × Berk-SAntilles), and Berk-S. The mean white counts were elevated 1.4- to 2.1-fold (P ≤ .01) in the Berk-SAntilles, NY-S/SAntilles, and Berk-S mice, but not in the NY-S mice compared with controls. Serum amyloid P-component (SAP), an acute-phase response protein with 60% to 70% sequence homology to CRP, was elevated 8.5- to 12.1-fold (P ≤ .001) in transgenic sickle mice. Similarly, serum interleukin-6 (IL-6) was elevated 1.6- to 1.9-fold (P ≤ .05). Western blots, confirming immunohistochemical staining, showed vascular cell adhesion molecule (VCAM), intercellular adhesion molecule (ICAM), and platelet-endothelial cell adhesion molecule (PECAM) were up-regulated 3- to 5-fold (P ≤ .05) in the lungs of sickle mice. Ribonuclease protection assays (RPAs) demonstrated VCAM mRNA also was elevated in sickle mice 1.2- to 1.4-fold (P ≤ .01). Nuclear factor κB (NF-κB), a transcription factor critical for the inflammatory response, was elevated 1.9-fold (P ≤ .006) in NY-S sickle mouse lungs. We conclude that transgenic sickle mice are good models to study vascular inflammation and the potential benefit of anti-inflammatory therapies to prevent vaso-occlusion in sickle cell disease.Keywords
This publication has 72 references indexed in Scilit:
- Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease*Clinical and Laboratory Haematology, 2002
- Tissue factor expression by endothelial cells in sickle cell anemia.Journal of Clinical Investigation, 1998
- Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” AgentMedicine, 1996
- Enhanced Levels of Soluble VCAM-1 in Sickle Cell Patients and Their Specific Increment during Vasoocclusive CrisisClinical Immunology and Immunopathology, 1996
- Structure, Regulation and Function of NF-kappaBAnnual Review of Cell Biology, 1994
- Study of Platelet Function in Patients with Sickle Cell Anemia during Steady State and Vaso-Occlusive CrisisActa Haematologica, 1993
- Recurrent cerebral ischemia during hypertransfusion therapy in sickle cell anemiaThe Journal of Pediatrics, 1983
- Monocyte functions in sickle cell disordersJournal of Pediatric Hematology/Oncology, 1983
- Spontaneous oxygen radical generation by sickle erythrocytes.Journal of Clinical Investigation, 1982
- Sickle Cell Anemia, a Molecular DiseaseScience, 1949